Global Cord Blood (NYSE:CO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO – Get Rating) in a research report issued to clients and investors on Thursday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

CO stock opened at $2.34 on Thursday. Global Cord Blood has a 52-week low of $2.10 and a 52-week high of $6.31. The stock’s 50 day moving average is $3.64 and its two-hundred day moving average is $3.99. The company has a market capitalization of $284.43 million, a PE ratio of 3.55 and a beta of 0.39.

Global Cord Blood (NYSE:CO – Get Rating) last posted its quarterly earnings data on Monday, February 28th. The medical research company reported $0.17 earnings per share (EPS) for the quarter. Global Cord Blood had a return on equity of 11.42% and a net margin of 41.98%. The company had revenue of $49.78 million for the quarter.

Several hedge funds and other institutional investors have recently modified their holdings of CO. Oasis Management Co Ltd. increased its holdings in shares of Global Cord Blood by 16.0% in the 4th quarter. Oasis Management Co Ltd. now owns 2,905,570 shares of the medical research company’s stock valued at $12,174,000 after acquiring an additional 400,636 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of Global Cord Blood by 130.4% in the 4th quarter. Qube Research & Technologies Ltd now owns 448,755 shares of the medical research company’s stock valued at $1,880,000 after acquiring an additional 253,949 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Global Cord Blood by 914.0% in the 4th quarter. Bank of America Corp DE now owns 221,265 shares of the medical research company’s stock valued at $927,000 after acquiring an additional 199,444 shares during the last quarter. Two Seas Capital LP bought a new stake in shares of Global Cord Blood in the 4th quarter valued at approximately $519,000. Finally, Verition Fund Management LLC bought a new stake in shares of Global Cord Blood in the 3rd quarter valued at approximately $392,000. Institutional investors and hedge funds own 15.13% of the company’s stock.

Global Cord Blood Company Profile (Get Rating)

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services.

Featured Articles